key: cord-0746965-gtfk2wtj
authors: Yano, Hisakazu; Nakano, Ryuichi; Suzuki, Yuki; Nakano, Akiyo; Kasahara, Kei; Hosoi, Hiroshi
title: Inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by gaseous ozone treatment
date: 2020-10-10
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2020.10.004
sha: 5032e372890964559a242069fcc940c0e38835ae
doc_id: 746965
cord_uid: gtfk2wtj

nan

of COVID-19, has become a worldwide pandemic [1] . The symptoms of COVID-19 vary widely 18 from asymptomatic disease to pneumonia, and COVID-19 is capable of causing life-threatening 19 complications such as acute respiratory distress syndrome, multisystem organ failure, and 20 ultimately death. Older patients and those with preexisting respiratory or cardio-vascular 21 conditions appear to be at the greatest risk for severe complications. 22

Ozone gas is effective against the majority of microorganisms tested by numerous 23 research groups, and relatively low concentrations of ozone and short contact time are sufficient 24 to inactivate bacteria, fungus, parasites, and viruses [2-5]. Because of this, ozone should be 25 considered for adoption as an effective weapon in the global fight against COVID-19. In this 26 study, we evaluated the efficacy of ozone gas for inactivation of SARS-CoV-2. 27

We used the SARS-CoV-2 (JPN/TY/WK-521) strain, which was isolated and provided by 28 the National Institute of Infectious Diseases, Japan. The SARS-CoV-2 culture was performed 29 using VeroE6/TMPRSS2 cells (JCRB1819). Virus culture broths were harvested by two cycles of 30 freezing and thawing and clarified by centrifugation at 10 000 g for 15 min at 4 °C. We subjected 31 the supernatant to ultrafiltration (Amicon Ultra-15; Merck Millipore Ltd., IRL), followed by 32 three washing steps with PBS. A sample (50 µL; 8.5 × 10 5 PFU) of viral suspension was 33 deposited on a 3 cm 2 area of stainless steel plates. The plates were allowed to dry before exposure 34 ozone-proof airtight acrylic box (H: 23 cm, D: 30 cm, W: 40 cm) with the device generating 36 ozone gas (TM-04OZ; Tamura TECO Ltd., Japan) and were 15 cm away from the device. The 37 plates were then exposed at a concentration of 1.0 ppm ozone for 60 minutes (CT value 60) and The plaque assay before exposure of ozone was 1.7 × 10 7 PFU/mL. The titre after exposure of 1.0 ppm ozone at 60 minutes was 1.7 × 10 4 compared with 5.8 × 10 5 PFU/mL for the 48 control. After exposure to 6.0 ppm ozone at 55 minutes the titre was less than or equal to 1.0 × 49 10 3 PFU/mL, compared with 2.0 × 10 6 PFU/mL for the control. The titre decreased significantly 50 following exposure to ozone, suggesting that ozone inactivated SARS-CoV-2. 51 J o u r n a l P r e -p r o o f ppm to 20 ppm for shorter periods [2, 3]. Using higher ozone concentrations for shorter periods 53 may make the process more logistically feasible in busy hospitals where short room turnaround 54 times are required. Although, since it is acknowledged that high concentrations can damage 55 equipment and items, the use of lower concentrations may be desirable in some situations. The 56 low concentration device we used would be better suited for use at night when there are no 57 patients. 58

The transmission routes of SARS-CoV-2 include droplet transmission, including cough, 59 sneeze, and droplet inhalation transmission. In addition, SARS-CoV-2 may spread by contact 60 transmission and be acquired in numerous indoor public spaces, including hospitals. The surface 61 environment in patient's room may be frequently contaminated [7, 8] , and contact with these 62 contaminated surfaces may result in hand contamination of healthcare personnel that may be 63

WHO declares COVID-19 a pandemic

Enveloped Virus 82 Inactivation on Personal Protective Equipment by Exposure to Ozone

Inactivation of Norovirus by ozone gas in conditions 85 relevant to healthcare

Ozone gas is an effective and practical antibacterial agent

Bactericidal properties of ozone and its potential application as 90

A study of the relationship 97 between environmental contamination with methicillin-resistant Staphylococcus aureus (MRSA) 98 and patients' acquisition of MRSA

Dissemination of antibiotic-resistant 101

enterococci within the ward environment: the role of airborne bacteria and the risk posed by 102 unrecognized carriers